Hera Biotech closes $1.9M seed funding for endometriosis diagnostics
The San Antonio-based biotechnology startup Hera Biotech has closed an oversubscribed $1.9 million seed financing round that will help the company bring the world's first non-surgical diagnostic test for endometriosis to market.
The seed funding will go to completing the in-patient human clinical study for their test called MetriD. Funding will also help Hera expand its intellectual property (IP) portfolio and finalize the new diagnostic's regulatory pathway with the Food and Drug Administration (FDA).
The seed round was fueled mostly by individual female supporters and investment firms Coyote Ventures, Stella Angels, Althea Group Ventures, and the Kendra Scott Women’s Entrepreneurial Leadership Institute.
“The Kendra Scott Women's Entrepreneurial Leadership Institute (KS WELI) at The U...